ArticleRegenerative biomaterials2025
Design and evaluation of ionically crosslinked multifunctional ELP-SA composite hydrogels for 3D cell culture.
Article in Regenerative biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydrogels are 3D crosslinked polymeric networks that can absorb and retain substantial quantities of water or biological fluids. Their soft, hydrated nature and adjustable properties render them highly suitable for a range of biomedical applications, such as drug delivery, tissue engineering and wound healing, by emulating the extracellular matrix. To overcome the limitations associated with the mechanical properties and biological functions of conventional elastin-like polypeptide (ELP) and sodium alginate (SA) hydrogels, a novel ion-responsive two-component ELP-SA hydrogel was developed. ELP variants with functional modules (ELPK/ELPR/ELPS/ELPL) were engineered through genetic techniques and purified to a high degree of purity (>95%) using high-salt-reversible phase-change technology. The release of Ca
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.